Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study

Rene Costello, Karina Espana, Neha Korde, MD, Mary Kwok, MD, Adriana Zingone, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine Calvo, MD, PhD, Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 5065.

https://doi.org/10.1182/blood.V118.21.5065.5065

Published: 2011

Journal Articles

CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia

Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Neha Korde, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Ola Landgren, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD

Blood (2011) 118 (21): 2880.

https://doi.org/10.1182/blood.V118.21.2880.2880

Published: 2011

Journal Articles

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Adriana Zingone, MD, PhD, Neha Korde, MD, Jinqiu Chen, PhD, Liqiang Xi, MD, Mark Raffeld, MD, Beata Holkova, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, Austin Doyle, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Christina Annunziata, MD, PhD, Steven Grant, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 306.

https://doi.org/10.1182/blood.V118.21.306.306

Published: 2011

Journal Articles

Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study

Esther Tan, MD, Liza Lindenberg, MD, Neha Korde, MD, Alexandra Berg, Esther Mena, MD, Baris Turkbey, MD, Omer Aras, MD, Seth M. Steinberg, PhD, Brendan Weiss, MD, Alex Minter, MD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Peter Choyke, MD, Karen Kurdziel, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 2888.

https://doi.org/10.1182/blood.V118.21.2888.2888

Published: 2011

Journal Articles

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Neha Korde, MD, Jane Trepel, Mattias Carlsten, MD Ph.D, Adriana Zingone, MD, PhD, Rene Costello, Mary Ann Yancey, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine Calvo, MD, PhD, Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Min-Jung Lee, MD, Sylvia Alarcon, George Carter, PA, Richard Childs, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 2944.

https://doi.org/10.1182/blood.V118.21.2944.2944

Published: 2011

NARROW

Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study

CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study

CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only